Aclaris Therapeutics (NASDAQ:ACRS) held its 2026 Annual Meeting of Stockholders virtually on Thursday, June 4, with shareholders approving all three proposals presented during the formal portion of the meeting, according to the company’s meeting transcript.
Neal Walker, Chief Executive Officer and Chair of the Board of Directors, opened the meeting and said the virtual format was intended “to facilitate stockholder participation.” Walker introduced members of the board and management team in attendance, including board members Vin Milano and Chris Molineaux; President and Chief Operating Officer Hugh Davis; Chief Financial Officer Kevin Balthaser; Chief Scientific Officer Roland Kolbeck; Chief Medical Officer Jesse Hall; Chief Business Officer Jim Lara; and General Counsel and Corporate Secretary Matthew Rothman.
Quorum Established
The company reported that proxy materials were mailed or made available beginning April 23, 2026, to stockholders of record as of April 14, 2026. The Inspector of Election reported that proxies had been received for 112,499,671 of the 139,663,680 shares of common stock outstanding on the record date.
That represented 80.55% of total outstanding shares, which constituted a quorum and allowed the company to proceed with the official business of the meeting.
Shareholders Approve Three Proposals
Stockholders voted on three proposals during the meeting:
- Election of directors: Anand Mehra and Maxine Gowen were elected as Class II directors to serve until the 2029 Annual Meeting of Stockholders and until their successors are elected and qualified.
- Executive compensation: Shareholders approved, on an advisory basis, the compensation of the company’s named executive officers as described in the proxy statement.
- Auditor ratification: Shareholders ratified the Audit Committee’s selection of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
The operator said the preliminary vote report showed that each of the proposals had carried or been approved. Aclaris said it expected to report the final voting results in a current report on Form 8-K to be filed with the Securities and Exchange Commission within four business days after the meeting.
No Stockholder Questions Submitted
After the formal business concluded, Walker opened the meeting for stockholder questions and comments submitted through the web portal. He said the company would attempt to answer as many questions as time allowed, limited to questions germane to the meeting.
No stockholder questions were submitted, and the meeting was adjourned shortly thereafter.
About Aclaris Therapeutics (NASDAQ:ACRS)
Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing novel small?molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non?melanoma skin lesions. Lead programs include ATI?50002, a topical agent in late?stage development for molluscum contagiosum removal; ATI?50003 for common wart resolution; ATI?1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI?450, an oral MK2 inhibitor for inflammatory indications.
Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.
